Agilent to appeal patent office decision on crispr grna patents

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a), announced today the company intends to appeal the u.s. patent and trademarks office (uspto) patent trial and appeal board's (ptab) final written decision in connection with the inter partes review (ipr) of u.s. patent nos. 10,337,001 & 10,900,034 (the agilent patents). the ptab recently reversed the uspto's original decision granting claims directed towards chemically modified synthetic crispr guide rna. agilent resp.
A Ratings Summary
A Quant Ranking